Johnson & Johnson (JNJ)
Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Johnson & Johnson JNJ will release earnings results for its fourth quarter, before the opening bell on Wednesday, Jan. 22, 2025.
Q4 Earnings: 3 Consumer Staples Titans on Deck
Among the bunch of companies expected to report in the coming days include a few consumer staples titans such as Procter & Gamble, Johnson & Johnson, and Kimberly-Clark.
Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?
Johnson & Johnson JNJ will be reporting its fourth-quarter earnings on Wednesday. Wall Street expects $2 in EPS and $22.44 billion in revenues as the company reports before market hours.
FDA approves Johnson & Johnson's nasal spray for depression as standalone treatment
The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow. The spray, called Spravato, is now the first-ever standalone therapy for treatment-resistant depression, which is when trying at least two standard treatments does little to nothing to improve depression symptoms in a patient.
US FDA approves J&J's ketamine-based therapy to treat depression
The U.S. Food and Drug Administration approved Johnson & Johnson's ketamine-based nasal spray Spravato, to treat adults with major depressive disorder, the company said on Tuesday.
Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Earnings?
JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Tremfya. It remains to be seen if MedTech sales improved.
What Analysts Think of Johnson & Johnson Stock Ahead of Earnings
Johnson & Johnson (JNJ) is set to report earnings before the bell Wednesday, with analysts expecting revenue and profit growth from the same time last year.
3 Super-Safe Dividend Stocks to Buy for 2025 and Beyond
Dividend cuts can be devastating to an income-focused investor. You lose a portion of your passive income, and a dividend stock's price tends to fall significantly leading up to and after a payout reduction.
Is Johnson & Johnson Stock Set to Reward Long-Term Holders?
In fact, Johnson & Johnson is one of the companies that is part of the exclusive dividend kings. The company has been increasing its dividend for 62 consecutive years, and the company's rock-solid balance sheet backs that dividend.
Johnson & Johnson: Q4 Earnings May Not Prompt Sustained Directional Moves
Johnson & Johnson has underperformed its lerge-cap healthcare peers and the S&P 500, with an -8% decline over the past year. Even though JNJ has displayed an improvingtrack record of beating consensus EPS,the Q4 earnings event, due to be held on the 22nd of Jan, may not significantly boost the stock. Question marks over the rising debt driven by M&A, the uncertainty surrounding the talcum powder lawsuits, slowing dividend growth and potentially lower FY25 EPS guidance may weigh heavily.
Insights Into Johnson & Johnson (JNJ) Q4: Wall Street Projections for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Johnson & Johnson (JNJ), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
J&J Seeks FDA Nod for Non-Muscle Invasive Bladder Cancer Drug
JNJ's regulatory filing seeks the FDA's approval for TAR-200, a drug-device combination for treating certain bladder cancer patients.
